- Price
- $400.32 → $376.59(−5.9%)
- Discount
- 15.7% → 20.7%(+5.0 pts)
- Next earnings
- 2026-10-27 → 2026-10-13
- Thesis
- In 2025, UnitedHealth's medical costs rose faster than expected2025 cost spike, mainly in Medicare Advantage. This, forced the company to withdraw its 2025a guidance withdrawal and replace itsa CEO change. TheIt left the market worries about an ongoingpricing the stock as though the business is still troubled. The medical care ratio has since improved for several straight quarters. The case for a re-rating rests on that trend continuing rather than reversing. It also rests on the outcome of the Department of Justice's investigation into Medicare Advantage billing, and about lasting reputational damage from the killing of. A large fine or a UnitedHealthcare executive in Decemberforced change to risk-coding practices would cut future revenue. A resolution with limited financial impact would remove a source of negative attention that has weighed on the stock since 2024. Since then, newNew management has delivered several straight quarters of improving medical cost ratiosis also selling down stakes in underperforming clinics, such as a September 2026 deal with TPG for Florida clinics, and stronger Optumcutting prior-authorization requirements starting October 2026. Both steps are meant to show the business model still works without the practices under scrutiny. The next Q3 2026 results, due October 13, 2026, will show whether the medical care ratio keeps improving into the back half of the year. Continued improvementIf it does, and the DOJ matter resolves without a severe penalty, the discount can showclose over the market thatnext two to four quarters. If a large fine or forced billing changes arrive instead, the 2025 cost spike was temporarymarket's caution would prove correct, not permanentand the stock could stay discounted well into 2027.
- Recent events
- 2026-09-09: UnitedHealth sold a minority stake in a group of Florida WellMed clinics, which focus on older patients, to private-equity firm TPG. Optum keeps an ownership interest and stays in the local market.
2026-07-16: UnitedHealth reported Q2 2026 revenue of $112.0 billion. The medical care ratio improved to 86.7%, from 89.4% a year earlier, and management raised full-year guidance.
2025-05-13: UnitedHealth withdrew its full-year 2025 earnings guidance. CEO Andrew Witty stepped down, and Stephen Hemsley returned as CEO.